Cellectar Biosciences develops drugs for cancer treatment. Its lead candidate, CLR 131, is in Phase 2 studies for B-cell malignancies and other lymphomas. Additional studies include pediatric solid tumors/lymphomas/malignant brain tumors and head and neck cancer. CLR 1900 is a preclinical PDC chemotherapeutic program for solid tumors. The company collaborates with Orano Med and LegoChemBio. Founded in 2002, its headquartered in Florham Park, New Jersey.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.3 |